Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021)
Karyopharm Therapeutics (KPTI) reported Asset Writedowns and Impairment of $200000.0 for Q3 2021, up 100.0% quarter-over-quarter from $100000.0 in Q2 2021.
Karyopharm Therapeutics (KPTI) Asset Writedowns and Impairment (2020 - 2021) Analysis & Trends
Karyopharm Therapeutics has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $200000.0 in Q3 2021.
- For the quarter ending Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $200000.0; the trailing twelve-month figure through Mar 2022 stood at $382000.0 (down 7.06% YoY), and the FY2020 full-year result was $329000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2021 stood at $200000.0, up from $100000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $329000.0 in Q4 2020, with the low at $82000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 200,000.00 |
| Sep 30, 2021 | 200,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 82,000.00 |
| Mar 31, 2021 | 82,000.00 |
| Dec 31, 2020 | 329,000.00 |
| Dec 31, 2020 | 329,000.00 |